Fig. 2

Vaccine platform development based on HIV-1 Virus-Like Particles. A Scheme of the linear polyprotein that generates the neoVLP. Signal peptide (SP) in light grey, Flag TAG in orange, neoantigens in blue, CD44 transmembrane domain © in yellow and HIV-1 Gag in green. B Drawing of a neoVLP displaying its components. C Representative flow cytometry contour plots analyzing the expression of neoVLP fusion proteins in transiently transfected Expi293F cells. Identification of Flag TAG at the surface of the cells and p24-Gag. Mock-transfected Expi293F cells were overlaid in each panel, in blue, for comparison purposes. D Representative flow cytometry contour plots analyzing the expression of neoVLP fusion proteins in transiently transfected Expi293F cells. Identification of total Flag TAG and p24-Gag. Mock-transfected Expi293F cells were overlaid in each panel, in blue, for comparison purpos© E TEM images of Expi293F cells producing neoVLP particles. F Workflow of neoVLP purification. G Cryo-TEM images of extracted (XAD4) neoVLPs. H Western blot image evaluating cell lysates (Pellet) and purified neoVLPs (VAX) from each type of VLP